Reaktion #1726709

ord-764a21ddb1184ccebf879e23a3e47f8b

Reaktionsgleichung

O=C1CCNCC1
4-piperidone
CC(=O)Nc1ccc(O)c(C(N)=O)c1
5-acetamido-2-hydroxybenzamide
C1COCCN1
morpholine
O=C1NC2(CCNCC2)Oc2ccccc21
Compound 9
O=C1NC2(CCNCC2)Oc2ccccc21
spiro[2H-1,3-benzoxazin-2,4′-piperidin]-4-(3H)-one

Lösungsmittel

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Aufarbeitung

  1. 1
    Temperaturis refluxed for 48 hr
  2. 2
    Waschenwashed with water, brine
  3. 3
    Trocknendried over Na2SO4
  4. 4
    SonstigeAfter solvent removal by rotoevaporation
  5. 5
    Sonstigethe crude product is purified by preparative TLC

Vorschrift

A mixture of 24 mg (0.077 mmol) of N-[4,8-dimethoxyquinoline-2-yl)carbonyl]-4-piperidone, 15 mg (0.077 mmol) of 5-acetamido-2-hydroxybenzamide, and 0.020 mL of morpholine in 3 mL of methanol is refluxed for 48 hr. The reaction mixture is diluted with ethyl acetate, and washed with water, brine, and dried over Na2SO4. After solvent removal by rotoevaporation, the crude product is purified by preparative TLC to give 11 mg (0.022 mmol, 30% yield) of 6-acetamido-1′-[4,8-dimethoxyquinoline-2-yl)carbonyl]spiro[2H-1,3-benzoxazin-2,4′-piperidin]-4-(3H)-one (Compound 9): 1H NMR (DMSO-d6): δ 2.02 (s, 3H), 3.95 (s, 3H), 4.06 (s, 3H), 7.03 (d, 1H), 8.19 (s, 1H), 7.24 (d of d, 1H), 7.52 (d of d, 1H), 7.67 (m, 2H), 8.02 (d, 1H), 8.82, (s, 1H) and 9.98 ppm (s, 1H). MS m/z: 491.1 (M+H)+, 513.2 (M+Na)+.

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US08110570B2uspto-grants-2012_02